SPL 1.03% 9.6¢ starpharma holdings limited

Ann: DEP outperforms leading treatments in ovarian cancer model, page-8

  1. 3,309 Posts.
    lightbulb Created with Sketch. 779
    Pre-clinical results from DEP-HER2 ADC in 2015.

    "We are very excited by these latest results for our targeted DEP ™ conjugates and feedback from commercial parties on this new data has been very positive indeed. Discussions are now underway with a number of pharmaceutical companies in relation to this targeted DEP conjugate …”

    Meanwhile, almost 9 years later ….


    Last edited by sarge17: 31/05/24
 
watchlist Created with Sketch. Add SPL (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.